Alerta

NEUROMODULATION TO TARGET GLUCOSE TRANSPORTER AND/OR INCRETIN PATHWAYS

Resumen de: US2025352127A1

The subject matter of the present disclosure generally relates to techniques for neuromodulation that include applying energy (e.g., ultrasound energy) into the tissue to cause a change in a glucose transporter pathway molecule and/or an incretin pathway molecule. In one embodiment, the neuromodulation is performed as a treatment of a metabolic disorder.

HOUSING FOR AN INTEGRATED GLUCOSE MONITORING SYSTEM

Resumen de: US2025352094A1

An integrated glucose monitoring system comprising a glucometer and mobile device housed in a housing. The glucometer includes a measurement component to receive a blood glucose test strip containing a sample of blood of an individual, and a port to transmit the blood glucose measurement to a mobile device. The mobile device communicatively and physically coupled to the glucometer. The mobile device includes a port configured to couple with the glucometer, a communication component to receive the blood glucose measurement from glucometer, a power management component to transmit power to the glucometer, and another port to receive power from a power source to power the mobile device. The housing is to house the glucometer and the mobile device to form a single solitary glucose monitoring system.

MODELING TARGETS OF CONTINUOUS GLUCOSE MONITORING METRICS FOR GLYCEMIC CONTROL

Resumen de: US2025352092A1

Disclosed herein are techniques for blood glucose management. In one example, a processor-implemented method includes receiving an input of a target value of a first continuous glucose monitoring (CGM) metric, estimating a target value of at least a second CGM metric that corresponds to the target value of the first CGM metric, and providing the estimated target value of at least the second CGM metric to a user. In some examples, the processor-implemented method also includes determining that the estimated target value of at least the second CGM metric meets a predetermined criterion, and configuring an insulin delivery system based on the target value of the first CGM metric.

CLOSED-LOOP BLOOD GLUCOSE CONTROL SYSTEMS AND METHODS

Resumen de: US2025352726A1

A control device (30) for determining a recommendation value of a control parameter of an insulin infusion device (20).

COMPOSITIONS AND METHODS FOR TREATING POSTURAL TACHYCARDIA SYNDROME

Resumen de: US2025353905A1

The present invention provides compositions and methods for treating Postural orthostatic tachycardia syndrome (POTS). In some embodiments, the POTS is associated with hypermobility spectrum disorders/hypermobile Ehlers-Danlos syndrome (HSD/hEDS). In various embodiments, the invention relates to administering a composition comprising an effective amount of a molecular antagonist of Glucose-dependent Insulinotropic Polpeptide (GIP) to a patient in need thereof. In various embodiments, the molecular antagonist can be provided in a form for convenient self-administration upon the onset of symptoms or to prevent or reduce postprandial POTS symptoms, or in other embodiments, is administered at a set frequency.

Apparatus for Optimizing A Patient's Insulin Dosage Regimen

Resumen de: US2025356983A1

An apparatus for optimizing a patient's insulin dosage regimen over time, comprising: at least a first computer-readable memory for storing data inputs corresponding at least to one or more components in a patient's present insulin dosage regimen and the patient's blood-glucose-level measurements determined at a plurality of times; a processor operatively connected to the at least first computer-readable memory, the processor programmed at least to determine from the data inputs corresponding to the patient's blood-glucose-level measurements determined at a plurality of times whether and by how much to vary at least one of the one or more components of the patient's present insulin dosage regimen in order to maintain the patient's future blood-glucose-level measurements within a predefined range; and a display operative to display information corresponding to at least the patient's present insulin dosage regimen.

System, device and method of dynamic glucose profile response to physiological parameters

Resumen de: AU2025259998A1

Method, device and system for providing consistent and reliable glucose response information to physiological changes and/or activities is provided to improve glycemic control and health management. Method, device and system for providing consistent and reliable glucose response information to physiological changes and/or activities is provided to improve glycemic control and health management. ov o v

MODELING TARGETS OF CONTINUOUS GLUCOSE MONITORING METRICS FOR GLYCEMIC CONTROL

Resumen de: EP4651146A1

Disclosed herein are techniques for blood glucose management. In one example, a processor-implemented method includes receiving an input of a target value of a first continuous glucose monitoring (CGM) metric, estimating a target value of at least a second CGM metric that corresponds to the target value of the first CGM metric, and providing the estimated target value of at least the second CGM metric to a user. In some examples, the processor-implemented method also includes determining that the estimated target value of at least the second CGM metric meets a predetermined criterion, and configuring an insulin delivery system based on the target value of the first CGM metric.

MEDICAL DEVICE DATA PROCESSING AND COMMUNICATION METHODS AND SYSTEMS

Resumen de: EP4649888A2

Methods and devices to monitor an analyte in body fluid are provided. Embodiments include continuous or discrete acquisition of analyte related data from a transcutaneously positioned in vivo analyte sensor automatically or upon request from a user. The detection and/or monitoring of glucose levels or other analytes, such as lactate, oxygen, AIC, or the like, in certain individuals is vitally important to their health. For example, the monitoring of glucose is particularly important to individuals with diabetes.

System and method for non-invasive blood glucose monitoring

Nº publicación: US12471808B1 18/11/2025

Solicitante:

UNIV SOUTH FLORIDA [US]
University of South Florida

Resumen de: US12471808B1

A system and method for continuous glucose monitoring (CGM) of blood in a blood vessel of a patient using a non-invasive sensor composed of a patch antenna operating in the Industrial, Scientific and Medical (ISM) Radio band (5.725 GHz-5.875 GHz). The device determines the blood glucose concentration of the blood in the blood vessel based on the measured shift of the resonant frequency of the non-invasive antenna patch sensor. A radio frequency (RF) synthesizer is used to drive the patch antenna with a fraction of its output coupled to both the antenna and receiver through a directional coupler. In this approach both the transmitted (FWD) and received (REV) power are processed, by demodulating logarithmic amplifiers, which convert the RF signals to corresponding voltages for downstream processing. The resulting voltages are then fed into a microcontroller and the measured shift in resonant frequency is converted to a real-time glucose concentration.